Immunology/Inflammation
Immunology/Inflammation(免疫及炎症)
The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.
Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].
BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].
Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.
Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].
References
[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.
[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.
[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.
[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.
[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.
[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.
[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.
[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.
- 5-Lipoxygenase(11)
- Papain(1)
- PGDS(1)
- PGE synthase(24)
- SIKs(12)
- IκB/IKK(67)
- AP-1(6)
- KEAP1-Nrf2(65)
- NOD1(1)
- TLR(140)
- NF-κB(241)
- Interleukin Related(171)
- 15-lipoxygenase(2)
- Others(63)
- Aryl Hydrocarbon Receptor(36)
- CD73(14)
- Complement System(58)
- Galectin(12)
- IFNAR(25)
- NO Synthase(77)
- NOD-like Receptor (NLR)(51)
- STING(110)
- Reactive Oxygen Species(465)
- Apoptosis(802)
- FKBP(20)
- eNOS(5)
- iNOS(29)
- nNOS(20)
- Glutathione(57)
- Adaptive Immunity(222)
- Allergy(130)
- Arthritis(34)
- Autoimmunity(190)
- Gastric Disease(101)
- Immunosuppressants(39)
- Immunotherapeutics(5)
- Innate Immunity(593)
- Pulmonary Diseases(119)
- Reactive Nitrogen Species(55)
- Reactive Sulfur Species(28)
- Specialized Pro-Resolving Mediators(50)
- Cyclic GMP-AMP Synthase(2)
- BCL6(3)
- CD20(3)
- CD22
- CD28(1)
- FAP(7)
- PSMA(7)
- Nuclear Factor of activated T Cells (NFAT)(1)
- Glycoprotein VI(1)
- Tim3(2)
- Hapten(1)
- Nectin-4(2)
Immunology/Inflammation 相关产品(4245)
- GC74247(+)-GlaucarubinoneCAS: 1259-86-5纯度: >96.00%
(+)-Glaucarubinone是一种强效的AP-1激活蛋白-1抑制剂,EC50值为0.13µM。
- GC74298Oxidized low density lipoprotein (Human)纯度: 不显示
Oxidized low density lipoprotein (Human)人ox-LDL参与动脉粥样硬化的形成。
- GC74304PSMA targeting peptide TFA纯度: >99.00%
PSMA targeting peptide TFA(PSMA-1 TFA)是一种PSMA靶向肽(GRFLTGGTGRLLRIS),可用于在PCa细胞中靶向递送葡萄糖调节蛋白(GRP)沉默siRNA。
- GC74402HYNIC-iPSMA TFACAS: 2375849-11-7纯度: >99.00%
HYNIC-iPSMA TFA是肿瘤分子成像的配体。nic ipsma由两个成分组成:nic(6-恶嗪诺丁酰胺)和ipsma(前列腺特异性膜抗原抑制剂)。
- GC74446RademikibartCAS: 2648260-80-2纯度: >98.00%
Rademikibart (CBP-201)是一种靶向IL-4Rα的人单克隆抗体,与人IL-4Rα表位结合时,KD为20.7 pM。
- GC74451Enfortumab vedotin-ejfv (solution)CAS: 1346452-25-2纯度: >99.00%
Enfortumab vedotin-ejfv (solution)是一种用于治疗尿路上皮癌的抗Nectin-4抗体药物偶联物。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC74227 | DOTA.SA.FAPi TFA | - | >99.00% | |
DOTA.SA.FAPi TFA是一种双功能DATA5m和DOTA螯合剂,由方酸和UAMC1110组成。 | ||||
| GC74247 | (+)-Glaucarubinone | 1259-86-5 | >96.00% | |
(+)-Glaucarubinone是一种强效的AP-1激活蛋白-1抑制剂,EC50值为0.13µM。 | ||||
| GC74252 | Euphornin | 80454-47-3 | >98.00% | |
Euphornin是一种抗癌剂,可从E. helioscopia中分离得到。 | ||||
| GC74256 | Condurango glycoside A | 11051-90-4 | >95.00% | |
Condurango glycoside A是p53的激活剂。 | ||||
| GC74267 | Propylparaben-d4 | 1219802-67-1 | >99.00% | |
Propylparaben-d4是氘标记的尼泊金丙酯。 | ||||
| GC74270 | Penduletin | 569-80-2 | >99.00% | |
Penduletin是一种黄酮类化合物,可以从白蜡和牡荆中分离出来。 | ||||
| GC74298 | Oxidized low density lipoprotein (Human) | - | 不显示 | |
Oxidized low density lipoprotein (Human)人ox-LDL参与动脉粥样硬化的形成。 | ||||
| GC74304 | PSMA targeting peptide TFA | - | >99.00% | |
PSMA targeting peptide TFA(PSMA-1 TFA)是一种PSMA靶向肽(GRFLTGGTGRLLRIS),可用于在PCa细胞中靶向递送葡萄糖调节蛋白(GRP)沉默siRNA。 | ||||
| GC74307 | 3BP-3940 | 2803421-14-7 | >99.00% | |
3BP-3940是一种用于治疗诊断的高效成纤维细胞活化蛋白(FAP)靶向肽。 | ||||
| GC74313 | MYBMIM | - | >99.00% | |
MYBMIM是MYB:CBP/P300复合物分子组装的抑制剂。 | ||||
| GC74317 | S7 | 853248-13-2 | >99.00% | |
S7是一种IL-6受体拮抗剂,抑制IL-6和IL-6R之间的结合。 | ||||
| GC74332 | N188 TFA | - | >99.00% | |
N188 TFA是一种基于双环肽骨架的放射性配体,靶向连接素-4,这是一种在许多肿瘤中过度表达的蛋白质。 | ||||
| GC74335 | Icotrokinra | 2763602-16-8 | >99.00% | |
Icotrokinra (JNJ-77242113)是一种口服的选择性IL-23受体拮抗剂。 | ||||
| GC74339 | Ac2-26 ammonium | - | >97.00% | |
Ac2-26 ammonium是膜联蛋白1的n端肽,具有抗炎活性。 | ||||
| GC74354 | Pegcetacoplan acetate | - | >98.00% | |
Pegcetacoplan acetate是一种聚乙二醇化的补体C3抑制剂肽。 | ||||
| GC74402 | HYNIC-iPSMA TFA | 2375849-11-7 | >99.00% | |
HYNIC-iPSMA TFA是肿瘤分子成像的配体。nic ipsma由两个成分组成:nic(6-恶嗪诺丁酰胺)和ipsma(前列腺特异性膜抗原抑制剂)。 | ||||
| GC74423 | Vamikibart | 2744320-12-3 | >99.00% | |
Vamikibart是一种靶向IL6的嵌合人源化IgG2κ抗体。 | ||||
| GC74425 | Casdozokitug | 2643331-37-5 | >96.00% | |
CasdozokitugSRF-388是一种针对IL27的IgG1κ抗体。 | ||||
| GC74439 | Picankibart | 2622900-74-5 | >98.00% | |
Picankibart是一种靶向IL23A的小鼠源性IgG1κ抗体。 | ||||
| GC74446 | Rademikibart | 2648260-80-2 | >98.00% | |
Rademikibart (CBP-201)是一种靶向IL-4Rα的人单克隆抗体,与人IL-4Rα表位结合时,KD为20.7 pM。 | ||||
| GC74451 | Enfortumab vedotin-ejfv (solution) | 1346452-25-2 | >99.00% | |
Enfortumab vedotin-ejfv (solution)是一种用于治疗尿路上皮癌的抗Nectin-4抗体药物偶联物。 | ||||
| GC74457 | Lunsekimig | - | >98.00% | |
Lunsekimig是一种抗tslp /IL13/ALB单克隆抗体,由5个顺序连接的可变区重链组成。 | ||||
| GC74471 | Camidanlumab | 921618-45-3 | >99.00% | |
Camidanlumab (HuMax-TAC)是一种CD25单克隆抗体。 | ||||
| GC74476 | Seribantumab | 1334296-12-6 | >95.00% | |
Seribantumab (MM 121)是一种靶向HER3的全人源IgG2单克隆抗体。 | ||||
